ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2077

IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis

Miho Suzuki1, Hiroto Yoshida2, Misato Hashizume1, Masashi Shiina2, Keisuke Tanaka1 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: animal models and steroids, glucocorticoids, interleukins (IL), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important that the dose steroids be reduced. However, some patients with chronic inflammatory disease may have difficulty tapering off steroids. It is thought that IL-6 might be involved in the steroid effects because elevated levels of IL-6 are found in these patients. Here, we elucidated the role of IL-6 in several effects of steroids using a collagen-induced arthritis (CIA) mouse model to examine the possibility of combination therapy.

Methods: To prepare a CIA model, DBA/1J mice were immunized intradermally with bovine type II collagen, and 21 days later (Day 21) once again given a booster injection. Mice were treated with the steroid prednisolone (PSL) intraperitoneally from Day 21 at doses of 1, 3, and 6 mg/kg five times a week or were administered with 8 mg of rat anti-mouse IL-6R monoclonal antibody (MR16-1) intraperitoneally once on Day 21. Another group was given a combination of the two from Day 21. Clinical symptoms of arthritis were evaluated by observation and expressed as an arthritis score on a scale of 0–4 for each limb. To assess the side effects of PSL, BMD was measured with DXA, and neutrophils and lymphocytes were quantified in blood using a sysmex system. Furthermore, synovial cells from CIA mice were cultured in the presence of dexamethasone (DEX) for 3 h after IL-6 pretreatment, and then COXII mRNA was quantified by real-time PCR.

Results: PSL dose-dependently reduced the arthritis score in the CIA model on the peak (Day 33) of arthritis. At the same time, neutrophil count was increased and lymphocyte count was decreased in a dose-dependent manner. MR16-1 in combination with low doses of PSL (1, 3 mg/kg) improved clinical symptoms significantly more than the same dose of PSL alone on Day 33 even though administration of MR16-1 alone resulted in no improvement. Interestingly, neutrophil and lymphocyte counts did not change and BMD was not reduced. To explore how MR16-1 could improve the anti-inflammatory effect of PSL, we next examined the influence of IL-6 on DEX activity in vitro. COXII expression was clearly suppressed by DEX, but IL-6 pretreatment attenuated the inhibitory effect of DEX.

Conclusion: We demonstrated that IL-6 blockade augmented the anti-inflammatory effect of PSL without changing BMD or neutrophil and lymphocyte counts in CIA mice. IL-6 blockade might make steroid tapering possible.


Disclosure:

M. Suzuki,
None;

H. Yoshida,
None;

M. Hashizume,
None;

M. Shiina,
None;

K. Tanaka,
None;

Y. Matsumoto,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-6-blockade-augments-the-anti-inflammatory-effect-without-increasing-the-side-effects-of-steroids-in-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology